ARC-520

DRUG6 trials

Sponsors

Arrowhead Pharmaceuticals

Conditions

Chronic Hepatitis BHealthyHepatitis BHepatitis B, ChronicHepatitis D

Phase 1

Safety and Tolerability Study of ARC-520 in Healthy Volunteers

CompletedNCT01872065

Arrowhead PharmaceuticalsHealthy

Start: 2013-07-31End: 2014-11-30Updated: 2025-12-26

A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers

CompletedNCT02535416

Arrowhead PharmaceuticalsHealthy

Start: 2015-09-30End: 2016-08-31Updated: 2026-01-13

Phase 2

A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection

TerminatedNCT02065336

Arrowhead PharmaceuticalsHepatitis B, Chronic

Start: 2014-03-31End: 2017-01-31Updated: 2026-01-13

Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus

TerminatedNCT02452528

Arrowhead PharmaceuticalsChronic Hepatitis B

Start: 2015-08-31End: 2016-12-31Updated: 2025-11-03

Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)

TerminatedNCT02577029

Arrowhead PharmaceuticalsHepatitis B, Hepatitis D

Start: 2015-12-31End: 2016-12-31Updated: 2026-01-13

A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection

TerminatedNCT02604212

Arrowhead PharmaceuticalsHepatitis B

Start: 2015-11-30End: 2016-12-31Updated: 2026-01-13

Related Papers

Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment

Gut2021-03-1243 citations